Pfizer (PFE) Total Non-Current Liabilities (2009 - 2026)

Pfizer has disclosed Total Non-Current Liabilities across 18 years of filings, most recently posting $113.5 billion for Q1 2026.

• In Q1 2026, Total Non-Current Liabilities rose 1.65% year-over-year to $113.5 billion; the TTM figure through Mar 2026 stood at $113.5 billion (up 1.65% YoY), while the FY2025 annual figure was $5.7 billion, down 7.57% from the prior year.
• Total Non-Current Liabilities grew to $113.5 billion in Q1 2026, from $5.7 billion in the prior quarter.
• Over the last five years, Total Non-Current Liabilities for PFE reached as high as $121.0 billion in Q3 2024 and fell as low as $5.7 billion in Q4 2025.
• The 5-year median for Total Non-Current Liabilities is $102.0 billion (2025), against an average of $77.6 billion.
• Annual changes were most pronounced in 2023 — Total Non-Current Liabilities surged 537.15% — and 2025, when it fell 15.69%.
• A 5-year view of Total Non-Current Liabilities shows it stood at $6.0 billion in 2022, then climbed by 0.03% to $6.0 billion in 2023, then climbed by 3.45% to $6.2 billion in 2024, then dropped by 7.57% to $5.7 billion in 2025, then soared by 1879.23% to $113.5 billion in 2026.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $113.5 billion, $5.7 billion, and $102.0 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.